| Place of Origin: | China |
|---|---|
| Brand Name: | Senwayer Brand |
| Certification: | ISO, 9001, USP |
| Model Number: | 129453-61-8 |
| Minimum Order Quantity: | 10grams |
| Price: | Discount is possible if your order is big enough |
| Packaging Details: | 10g, 20g, 50g , 100g, 500g. 1kg, 10kg |
| Delivery Time: | within 2 working days |
| Payment Terms: | T/T in advance, Money Gram, Western Union, Bank Transfer. |
| Supply Ability: | 1000kg/month |
| CAS: | 129453-61-8 | Alias: | Fulvestrant , Faslodex |
|---|---|---|---|
| Apparence: | Almost White Crystalline Powder | Purity: | 99% |
| High Light: | antineoplastic drugs,breast cancer drugs |
||
Mediacal Faslodex For Breast Cancer Treatment Hormones 129453-61-8 White Powder
Quick detail
| Product Name | Fulvestrant , Faslodex |
| Chemical Name | Faslodex |
| CAS Number | 129453-61-8 |
| Molecular Formula | C32H47F5O3S |
| Molecular Weight | 606.77 |
| Melting Point | 104-106ºC |
| Assay | 99.5% |
| Appearance | White powder |
| Product Categories | Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & SeleniumCompounds;FASLODEX;Anti-cancer&immunity;Inhibitors |
Fulvestrant Description:
Fulvestrant, sold under the trade name Faslodex among others, is used to treat hormone receptor positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods) and whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen (Nolvadex). It works to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Fulvestrant is approved to treat:
Breast cancer in postmenopausal women. It is used in patients with estrogen receptor positive breast cancer that has metastasized (spread to other parts of the body) after treatment with other antiestrogens.
Usual Adult Dose for Breast Cancer
Initial dose: 500 mg IM on days 1, 15, and 29, then once a month thereafter.
Renal Dose Adjustments
CrCl 30 mL/min or more: No adjustment recommended
CrCl 29 mL/min or less: Data not available
Liver Dose Adjustments
Mild liver function (Child-Pugh class A): No specific dose adjustment guidelines have been suggested; however, caution is recommended.
Moderate liver dysfunction (Child-Pugh class B): 250 mg IM on days 1, 15, and 29, then once a month thereafter.
Severe liver dysfunction (Child-Pugh class C): Data not available
Precautions
Women of childbearing age should be advised not to become pregnant while receiving fulvestrant.
Because fulvestrant is administered intramuscularly it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or patients on anticoagulants.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Fulvestrante COA:
| Test Item | Specification | Results | |
| Appearance | A white to off-white crystalline powder | A white crystalline powder | |
| Identification | IR | Conform | |
| Any Individual impurity | Not more than 0.10% | 0.18% | |
| Total impurities | Not more than 1.0% | 0.44% | |
Ratio of isomers |
50.0%-60.0% | 51.70% | |
| 40.0%-50.0% | 47.86% | ||
| Purity | 99.0% | 99.56% | |
